Research Reports

Key takeaways

Revenue increased 8.7% to $2.3M from $2.1M, reflecting higher product sales including from the biomedical market segment.

Gross profit rose 19.7% to $1.4M from $1.1M, with margins expanding to 58.8% due to a slight sales mix shift toward higher-margin biomedical products.

Operating loss narrowed 11.6% to -$190K from -$215K, supported by gross profit gains despite operating expense pressures.

Net loss improved 14.1% to -$220K from -$256K, with diluted EPS steady at -$0.03.

Net cash from operations was $121K versus $227K prior year, yielding $98K free cash flow after $23K capex.

Management focuses on cash flow management, capex timing, and raising capital to fund R&D and operations.

Full analysis

Cash flow from operations totaled $121 thousand, down from $227 thousand year-over-year, after accounting for non-cash adjustments including $222 thousand in stock-based compensation, depreciation, amortization, lease expense, inventory reserves, and related-party note interest. Capital expenditures rose to $23 thousand from $5 thousand, primarily for equipment and patents, resulting in $98 thousand free cash flow. Management's plans emphasize prudent cash management, timed investments, and pursuing financing to support research and development programs and ongoing operations. The company intends to refine manufacturing processes and supply chain for both LCT and LSC segments to further improve cost of sales as a percentage of revenue. These efforts aim to sustain momentum, though results are not necessarily indicative of future performance.

ISCO · International Stem Cell Corporation

Summary

Key takeaways

Full analysis